Loading…
Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study
Background Patients with cancer, particularly those undergoing chemotherapy, are at risk from the low immunogenicity of Coronavirus Disease 19 (COVID-19) vaccines. Methods This prospective study assessed the seroconversion rate of COVID-19 vaccines among patients with cancer and hospital staff. Seve...
Saved in:
| Published in: | International journal of clinical oncology 2024-04, Vol.29 (4), p.386-397 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c426t-5fdbb91f3fb6824137c235f629dcb5a38fc8a1fde6e2531c374783081eb88f4d3 |
| container_end_page | 397 |
| container_issue | 4 |
| container_start_page | 386 |
| container_title | International journal of clinical oncology |
| container_volume | 29 |
| creator | Katsuya, Yuki Yoshida, Tatsuya Takashima, Atsuo Yonemori, Kan Ohba, Akihiro Yazaki, Shu Yagishita, Shigehiro Nakahama, Hiroko Kobayashi, Osamu Yanagida, Masatoshi Irino, Yasuhiro Hamada, Akinobu Yamamoto, Noboru |
| description | Background
Patients with cancer, particularly those undergoing chemotherapy, are at risk from the low immunogenicity of Coronavirus Disease 19 (COVID-19) vaccines.
Methods
This prospective study assessed the seroconversion rate of COVID-19 vaccines among patients with cancer and hospital staff. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG (S-IgG) concentrations were evaluated before the first vaccination, and 1–3 and 4–6 months after the second vaccination. The primary endpoint was the seroconversion rate measured 1–3 months after the second vaccine.
Results
In total, 590 patients and 183 healthy hospital staff were analyzed. At 1–3 months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU/mL) in 96.1% (567/590) of the patients with cancer and 100% (183/183) of the healthy controls (
p
= 0.0024). At 4–6 months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU/ml for S-IgG) in 93.1% (461/495) of the patients with cancer and 100% (170/170) of the healthy controls (
p
|
| doi_str_mv | 10.1007/s10147-024-02470-x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10963526</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2983826722</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-5fdbb91f3fb6824137c235f629dcb5a38fc8a1fde6e2531c374783081eb88f4d3</originalsourceid><addsrcrecordid>eNp9kctu1DAUhi0EoqXwAiyQJTYsGvAlsRM2CA23kSp1A2wtxzmeukrsYDtDZ8ej4-kM5bJgYdny-c5_Lj9CTyl5SQmRrxIltJYVYfX-SFLd3EOntOayklKy--XNa1p1gjUn6FFK14RQKRr2EJ3wlreUCn6KfqynafFhA94Zl3dY2wwRb7UxzuvsgsfB4tXl1_W7inbHf0jYeTyXMPic8HeXr7DR3kB8jTWeY0gzmOy2cI6T85sRsCkgxHMc-gRxe6urR5zyMuweowdWjwmeHO8z9OXD-8-rT9XF5cf16u1FZWomctXYoe87arntRctqyqVhvLGCdYPpG81ba1pN7QACWMOp4bKWLScthb5tbT3wM_TmoDsv_QTDvqOoRzVHN-m4U0E79XfEuyu1CVtFSSd4w0RReHFUiOHbAimrySUD46g9hCUp1rGuqQkhXUGf_4NehyWWmfdU2T0TkrFCsQNlyspSBHvXDSVq77A6OKyKu-rWYXVTkp79Ocddyi9LC8APQCohv4H4u_Z_ZH8CUSa0Hg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2983826722</pqid></control><display><type>article</type><title>Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study</title><source>Springer Nature</source><creator>Katsuya, Yuki ; Yoshida, Tatsuya ; Takashima, Atsuo ; Yonemori, Kan ; Ohba, Akihiro ; Yazaki, Shu ; Yagishita, Shigehiro ; Nakahama, Hiroko ; Kobayashi, Osamu ; Yanagida, Masatoshi ; Irino, Yasuhiro ; Hamada, Akinobu ; Yamamoto, Noboru</creator><creatorcontrib>Katsuya, Yuki ; Yoshida, Tatsuya ; Takashima, Atsuo ; Yonemori, Kan ; Ohba, Akihiro ; Yazaki, Shu ; Yagishita, Shigehiro ; Nakahama, Hiroko ; Kobayashi, Osamu ; Yanagida, Masatoshi ; Irino, Yasuhiro ; Hamada, Akinobu ; Yamamoto, Noboru</creatorcontrib><description>Background
Patients with cancer, particularly those undergoing chemotherapy, are at risk from the low immunogenicity of Coronavirus Disease 19 (COVID-19) vaccines.
Methods
This prospective study assessed the seroconversion rate of COVID-19 vaccines among patients with cancer and hospital staff. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG (S-IgG) concentrations were evaluated before the first vaccination, and 1–3 and 4–6 months after the second vaccination. The primary endpoint was the seroconversion rate measured 1–3 months after the second vaccine.
Results
In total, 590 patients and 183 healthy hospital staff were analyzed. At 1–3 months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU/mL) in 96.1% (567/590) of the patients with cancer and 100% (183/183) of the healthy controls (
p
= 0.0024). At 4–6 months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU/ml for S-IgG) in 93.1% (461/495) of the patients with cancer and 100% (170/170) of the healthy controls (
p
< 0.0001). Old age, being male, and low lymphocyte count were related to low SARS-CoV-2 S-IgG levels 1–3 months after the second vaccination among patients, while body mass index, smoking history, and serum albumin level were not. Patients undergoing platinum combination therapy and alkylating agent among cytotoxic drugs, and PARP inhibitor, mTOR inhibitor, and BCR-ABL inhibitor exhibited a low S-IgG antibody concentration compared to the no treatment group.
Conclusions
COVID-19 vaccine immunogenicity was reduced among patients with cancer, especially under several treatment regimens.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-024-02470-x</identifier><identifier>PMID: 38381163</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Antibodies ; Antibodies, Viral ; BCR-ABL protein ; Body mass index ; Cancer ; Cancer Research ; Cancer therapies ; Cancer vaccines ; Cell number ; Chemotherapy ; Coronaviruses ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - therapeutic use ; Cytotoxicity ; Female ; Fusion protein ; Humans ; Immunization ; Immunogenicity ; Immunoglobulin G ; Infant ; Lymphocytes ; Male ; Medicine ; Medicine & Public Health ; Neoplasms - drug therapy ; Oncology ; Original ; Original Article ; Patients ; Prospective Studies ; SARS-CoV-2 ; Seroconversion ; Severe acute respiratory syndrome coronavirus 2 ; Spike protein ; Surgical Oncology ; TOR protein ; Vaccination</subject><ispartof>International journal of clinical oncology, 2024-04, Vol.29 (4), p.386-397</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c426t-5fdbb91f3fb6824137c235f629dcb5a38fc8a1fde6e2531c374783081eb88f4d3</cites><orcidid>0000-0002-2127-3601</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38381163$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Katsuya, Yuki</creatorcontrib><creatorcontrib>Yoshida, Tatsuya</creatorcontrib><creatorcontrib>Takashima, Atsuo</creatorcontrib><creatorcontrib>Yonemori, Kan</creatorcontrib><creatorcontrib>Ohba, Akihiro</creatorcontrib><creatorcontrib>Yazaki, Shu</creatorcontrib><creatorcontrib>Yagishita, Shigehiro</creatorcontrib><creatorcontrib>Nakahama, Hiroko</creatorcontrib><creatorcontrib>Kobayashi, Osamu</creatorcontrib><creatorcontrib>Yanagida, Masatoshi</creatorcontrib><creatorcontrib>Irino, Yasuhiro</creatorcontrib><creatorcontrib>Hamada, Akinobu</creatorcontrib><creatorcontrib>Yamamoto, Noboru</creatorcontrib><title>Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>Int J Clin Oncol</addtitle><description>Background
Patients with cancer, particularly those undergoing chemotherapy, are at risk from the low immunogenicity of Coronavirus Disease 19 (COVID-19) vaccines.
Methods
This prospective study assessed the seroconversion rate of COVID-19 vaccines among patients with cancer and hospital staff. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG (S-IgG) concentrations were evaluated before the first vaccination, and 1–3 and 4–6 months after the second vaccination. The primary endpoint was the seroconversion rate measured 1–3 months after the second vaccine.
Results
In total, 590 patients and 183 healthy hospital staff were analyzed. At 1–3 months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU/mL) in 96.1% (567/590) of the patients with cancer and 100% (183/183) of the healthy controls (
p
= 0.0024). At 4–6 months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU/ml for S-IgG) in 93.1% (461/495) of the patients with cancer and 100% (170/170) of the healthy controls (
p
< 0.0001). Old age, being male, and low lymphocyte count were related to low SARS-CoV-2 S-IgG levels 1–3 months after the second vaccination among patients, while body mass index, smoking history, and serum albumin level were not. Patients undergoing platinum combination therapy and alkylating agent among cytotoxic drugs, and PARP inhibitor, mTOR inhibitor, and BCR-ABL inhibitor exhibited a low S-IgG antibody concentration compared to the no treatment group.
Conclusions
COVID-19 vaccine immunogenicity was reduced among patients with cancer, especially under several treatment regimens.</description><subject>Antibodies</subject><subject>Antibodies, Viral</subject><subject>BCR-ABL protein</subject><subject>Body mass index</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Cancer vaccines</subject><subject>Cell number</subject><subject>Chemotherapy</subject><subject>Coronaviruses</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - therapeutic use</subject><subject>Cytotoxicity</subject><subject>Female</subject><subject>Fusion protein</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Immunoglobulin G</subject><subject>Infant</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasms - drug therapy</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>SARS-CoV-2</subject><subject>Seroconversion</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike protein</subject><subject>Surgical Oncology</subject><subject>TOR protein</subject><subject>Vaccination</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kctu1DAUhi0EoqXwAiyQJTYsGvAlsRM2CA23kSp1A2wtxzmeukrsYDtDZ8ej4-kM5bJgYdny-c5_Lj9CTyl5SQmRrxIltJYVYfX-SFLd3EOntOayklKy--XNa1p1gjUn6FFK14RQKRr2EJ3wlreUCn6KfqynafFhA94Zl3dY2wwRb7UxzuvsgsfB4tXl1_W7inbHf0jYeTyXMPic8HeXr7DR3kB8jTWeY0gzmOy2cI6T85sRsCkgxHMc-gRxe6urR5zyMuweowdWjwmeHO8z9OXD-8-rT9XF5cf16u1FZWomctXYoe87arntRctqyqVhvLGCdYPpG81ba1pN7QACWMOp4bKWLScthb5tbT3wM_TmoDsv_QTDvqOoRzVHN-m4U0E79XfEuyu1CVtFSSd4w0RReHFUiOHbAimrySUD46g9hCUp1rGuqQkhXUGf_4NehyWWmfdU2T0TkrFCsQNlyspSBHvXDSVq77A6OKyKu-rWYXVTkp79Ocddyi9LC8APQCohv4H4u_Z_ZH8CUSa0Hg</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Katsuya, Yuki</creator><creator>Yoshida, Tatsuya</creator><creator>Takashima, Atsuo</creator><creator>Yonemori, Kan</creator><creator>Ohba, Akihiro</creator><creator>Yazaki, Shu</creator><creator>Yagishita, Shigehiro</creator><creator>Nakahama, Hiroko</creator><creator>Kobayashi, Osamu</creator><creator>Yanagida, Masatoshi</creator><creator>Irino, Yasuhiro</creator><creator>Hamada, Akinobu</creator><creator>Yamamoto, Noboru</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2127-3601</orcidid></search><sort><creationdate>20240401</creationdate><title>Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study</title><author>Katsuya, Yuki ; Yoshida, Tatsuya ; Takashima, Atsuo ; Yonemori, Kan ; Ohba, Akihiro ; Yazaki, Shu ; Yagishita, Shigehiro ; Nakahama, Hiroko ; Kobayashi, Osamu ; Yanagida, Masatoshi ; Irino, Yasuhiro ; Hamada, Akinobu ; Yamamoto, Noboru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-5fdbb91f3fb6824137c235f629dcb5a38fc8a1fde6e2531c374783081eb88f4d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibodies</topic><topic>Antibodies, Viral</topic><topic>BCR-ABL protein</topic><topic>Body mass index</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Cancer vaccines</topic><topic>Cell number</topic><topic>Chemotherapy</topic><topic>Coronaviruses</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - therapeutic use</topic><topic>Cytotoxicity</topic><topic>Female</topic><topic>Fusion protein</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Immunoglobulin G</topic><topic>Infant</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasms - drug therapy</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>SARS-CoV-2</topic><topic>Seroconversion</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike protein</topic><topic>Surgical Oncology</topic><topic>TOR protein</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katsuya, Yuki</creatorcontrib><creatorcontrib>Yoshida, Tatsuya</creatorcontrib><creatorcontrib>Takashima, Atsuo</creatorcontrib><creatorcontrib>Yonemori, Kan</creatorcontrib><creatorcontrib>Ohba, Akihiro</creatorcontrib><creatorcontrib>Yazaki, Shu</creatorcontrib><creatorcontrib>Yagishita, Shigehiro</creatorcontrib><creatorcontrib>Nakahama, Hiroko</creatorcontrib><creatorcontrib>Kobayashi, Osamu</creatorcontrib><creatorcontrib>Yanagida, Masatoshi</creatorcontrib><creatorcontrib>Irino, Yasuhiro</creatorcontrib><creatorcontrib>Hamada, Akinobu</creatorcontrib><creatorcontrib>Yamamoto, Noboru</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katsuya, Yuki</au><au>Yoshida, Tatsuya</au><au>Takashima, Atsuo</au><au>Yonemori, Kan</au><au>Ohba, Akihiro</au><au>Yazaki, Shu</au><au>Yagishita, Shigehiro</au><au>Nakahama, Hiroko</au><au>Kobayashi, Osamu</au><au>Yanagida, Masatoshi</au><au>Irino, Yasuhiro</au><au>Hamada, Akinobu</au><au>Yamamoto, Noboru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><addtitle>Int J Clin Oncol</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>29</volume><issue>4</issue><spage>386</spage><epage>397</epage><pages>386-397</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>Background
Patients with cancer, particularly those undergoing chemotherapy, are at risk from the low immunogenicity of Coronavirus Disease 19 (COVID-19) vaccines.
Methods
This prospective study assessed the seroconversion rate of COVID-19 vaccines among patients with cancer and hospital staff. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG (S-IgG) concentrations were evaluated before the first vaccination, and 1–3 and 4–6 months after the second vaccination. The primary endpoint was the seroconversion rate measured 1–3 months after the second vaccine.
Results
In total, 590 patients and 183 healthy hospital staff were analyzed. At 1–3 months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU/mL) in 96.1% (567/590) of the patients with cancer and 100% (183/183) of the healthy controls (
p
= 0.0024). At 4–6 months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU/ml for S-IgG) in 93.1% (461/495) of the patients with cancer and 100% (170/170) of the healthy controls (
p
< 0.0001). Old age, being male, and low lymphocyte count were related to low SARS-CoV-2 S-IgG levels 1–3 months after the second vaccination among patients, while body mass index, smoking history, and serum albumin level were not. Patients undergoing platinum combination therapy and alkylating agent among cytotoxic drugs, and PARP inhibitor, mTOR inhibitor, and BCR-ABL inhibitor exhibited a low S-IgG antibody concentration compared to the no treatment group.
Conclusions
COVID-19 vaccine immunogenicity was reduced among patients with cancer, especially under several treatment regimens.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>38381163</pmid><doi>10.1007/s10147-024-02470-x</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-2127-3601</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-9625 |
| ispartof | International journal of clinical oncology, 2024-04, Vol.29 (4), p.386-397 |
| issn | 1341-9625 1437-7772 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10963526 |
| source | Springer Nature |
| subjects | Antibodies Antibodies, Viral BCR-ABL protein Body mass index Cancer Cancer Research Cancer therapies Cancer vaccines Cell number Chemotherapy Coronaviruses COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - therapeutic use Cytotoxicity Female Fusion protein Humans Immunization Immunogenicity Immunoglobulin G Infant Lymphocytes Male Medicine Medicine & Public Health Neoplasms - drug therapy Oncology Original Original Article Patients Prospective Studies SARS-CoV-2 Seroconversion Severe acute respiratory syndrome coronavirus 2 Spike protein Surgical Oncology TOR protein Vaccination |
| title | Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A08%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20after%20vaccination%20of%20COVID-19%20vaccines%20in%20patients%20with%20cancer:%20a%20prospective,%20single%20center,%20observational%20study&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Katsuya,%20Yuki&rft.date=2024-04-01&rft.volume=29&rft.issue=4&rft.spage=386&rft.epage=397&rft.pages=386-397&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-024-02470-x&rft_dat=%3Cproquest_pubme%3E2983826722%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c426t-5fdbb91f3fb6824137c235f629dcb5a38fc8a1fde6e2531c374783081eb88f4d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2983826722&rft_id=info:pmid/38381163&rfr_iscdi=true |